Latest Geographic Expansion News

TruScreen Group posted a NZ$2.25 million loss for FY2026, with its auditor highlighting material uncertainty over the company’s ability to continue without further funding. Revenue rose to NZ$2.4 million amid geographic expansion, but cash burn and accumulated losses remain significant.

Symal Group is set to significantly boost its defence and resources contracting presence through the $51 million acquisition of Shamrock Civil, a Queensland-based contractor with a $315 million pipeline dominated by defence projects.

Tasmea Limited is set to acquire Maxim Group for up to A$254 million, bolstering its presence in Victoria and accelerating exposure to high-growth sectors like Data Centres, BESS, and Infrastructure. The deal promises immediate EPS accretion of around 31% and positions Tasmea as one of the largest electrical contractors on the ASX.

XReality Group (ASX:XRG) posts strong FY26 revenue and ARR growth, marking key milestones with its first commercial MR-1 mixed reality sale to the US Department of Defense and debut European contract with the Swedish Armed Forces.

SSH Group has finalised its acquisition of Elphinstone Mechanical Services, significantly boosting its industrial mining services and workforce capabilities across Western Australia and Queensland.

Fluence Corporation Limited (ASX: FLC) reports a 52% revenue surge in FY2025 driven by strategic growth in Smart Product Solutions and recurring revenue, alongside progress on a major Ivory Coast water treatment plant.

Light & Wonder posted modest revenue growth in Q1 2026, driven by strong Gaming and iGaming performances, while net income fell sharply due to legacy legal costs. The company maintains disciplined capital management amid ongoing macro pressures.

SSH Group Ltd is set to acquire Elphinstone Mechanical Services, boosting its revenue scale and geographic reach into Queensland and New South Wales with an immediately accretive deal.

OpenLearning accelerated its SaaS annual recurring revenue by 35% year-on-year to $3.192 million in Q1 FY26, propelled by larger multi-year LMS contracts and ongoing AI platform enhancements.

Microba Life Sciences reported a 99% year-on-year surge in core testing revenue for Q3 FY26, propelled by strong test volume growth and new clinic contracts in Australia and the UK. The company is advancing a major product release and negotiating a significant corporate transaction to bolster its financial position.

Emyria reported $1.2 million revenue for Q1 2026 driven by insurer-funded clinics and expanded its Empax network across multiple states. It launched a Global Partnership Program targeting international drug sponsors, leveraging its clinical infrastructure amid growing global interest in psychedelic therapies.

Orthocell has secured approval for its Remplir™ nerve repair device to be used across 221 U.S. military and veterans hospitals, marking a major step in its U.S. commercial expansion. The approval follows clinical validation in conflict zones, positioning Orthocell to deepen penetration into defence healthcare.